If you are wondering whether IDEXX Laboratories at around US$589 per share is still a sensible entry or if you are late to ...

Idexx delivered revenue and EPS growth of 6% and 13% in Q4, but its guidance appears to have caught the market's attention. Looking ahead to 2025, management expects the company to grow sales by 4% to ...

IDEXX rides on strong diagnostics growth and software momentum, but FX pressure and weak solvency cloud its outlook - should ...

Shares of IDEXX Laboratories IDXX have rallied 39.1% over the past 12 months, showing impressive momentum. The stock has outpaced its industry, which rose 2.3%, as well as the S&P 500 Composite’s 29.6 ...

Ratings for IDEXX Laboratories (NASDAQ:IDXX) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview ...

IDEXX Laboratories (NASDAQ:IDXX) will release its quarterly earnings report on Monday, 2026-02-02. Here's a brief overview for investors ahead of the announcement. Analysts anticipate IDEXX ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Healthcare diagnostics equipment manufacturer, Idexx Laboratories (NASDAQ: IDXX), is the global leader in pet care. But here's an interesting tidbit: The company's shares have risen 10,230% since 2000 ...

IDEXX Laboratories is a leader in animal diagnostics, boasting strong recurring revenue and nearly 50% stock gains year-to-date. IDXX's innovation pipeline, robust cash position, and global reach ...

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tuesday, May 5, 2026, before the market ...

The humanization of pets megatrend should eventually power these stocks to new highs. Idexx Labs' expansion into oncology diagnostics for pets could reignite its decelerating sales growth. Zoetis' ...

Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic. Advances IDEXX's (IDXX) innovation ...